Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial

Abstract Context For children with growth hormone deficiency (GHD), treatment burden with daily somatropin injections [human growth hormone (hGH)] is high, which may lead to poor adherence and suboptimal overall treatment outcomes. Lonapegsomatropin (TransCon hGH) is an investigational long-acting, once-weekly prodrug for the treatment of GHD. Objective The objective of this study was to evaluate the efficacy and safety of once-weekly lonapegsomatropin vs daily somatropin. Design The heiGHt trial was a randomized, open-label, active-controlled, 52-week Phase 3 trial (NCT02781727). Setting This trial took place at 73 sites across 15 countries. Patients This trial enrolled and dosed 161 treatment-naïve, prepubertal patients with GHD. Interventions Patients were randomized 2:1 to receive lonapegsomatropin 0.24 mg hGH/kg/week or an equivalent weekly dose of somatropin delivered daily. Main Outcome Measure The primary end point was annualized height velocity (AHV) at week 52. Secondary efficacy end points included change from baseline in height SD scores (SDS). Results Least squares (LS) mean (SE) AHV at 52 weeks was 11.2 (0.2) cm/year for lonapegsomatropin vs 10.3 (0.3) cm/year for daily somatropin (P = 0.009), with lonapegsomatropin demonstrating both noninferiority and superiority over daily somatropin. LS mean (SE) height SDS increased from baseline to week 52 by 1.10 (0.04) vs 0.96 (0.05) in the weekly lonapegsomatropin vs daily somatropin groups (P = 0.01). Bone age/chronological age ratio, adverse events, tolerability, and immunogenicity were similar between groups. Conclusions The trial met its primary objective of noninferiority in AHV and further showed superiority of lonapegsomatropin compared to daily somatropin, with similar safety, in treatment-naïve children with GHD.

[1]  C. Deal,et al.  OR10-06 Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Pediatric Phase 3 Clinical Trial , 2020, Journal of the Endocrine Society.

[2]  A. Eliakim,et al.  Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial , 2020, The Journal of clinical endocrinology and metabolism.

[3]  W. Kiess,et al.  Long‐term safety of growth hormone—A combined registry analysis , 2018, Clinical endocrinology.

[4]  D. Karpf,et al.  The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency , 2017, Endocrine connections.

[5]  P. Chatelain,et al.  A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency , 2017, The Journal of clinical endocrinology and metabolism.

[6]  Raoul Rooman,et al.  Validation of Prediction Models for Near Adult Height in Children with Idiopathic Growth Hormone Deficiency Treated with Growth Hormone: A Belgian Registry Study , 2016, Hormone Research in Paediatrics.

[7]  P. Chanson,et al.  Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations , 2016, European journal of endocrinology.

[8]  K. Tunceli,et al.  Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy. , 2015, Clinical therapeutics.

[9]  T. Reinehr,et al.  Is growth hormone treatment in children associated with weight gain? – Longitudinal analysis of KIGS data , 2014, Clinical endocrinology.

[10]  K. Karason,et al.  GH and the cardiovascular system: an update on a topic at heart , 2014, Endocrine.

[11]  A. Doering,et al.  Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. , 2014, The Journal of clinical endocrinology and metabolism.

[12]  A. Döring,et al.  Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. , 2014, The Journal of clinical endocrinology and metabolism.

[13]  S. van Buuren,et al.  Personalized Approach to Growth Hormone Treatment: Clinical Use of Growth Prediction Models , 2013, Hormone Research in Paediatrics.

[14]  C. Acerini,et al.  Understanding the Growth Hormone Therapy Adherence Paradigm: A Systematic Review , 2013, Hormone Research in Paediatrics.

[15]  J. Deijen,et al.  The Involvement of the GH/IGF-I Axis in Cognitive Functions of Adult Patients and Healthy Subjects , 2012 .

[16]  A. Eliakim,et al.  Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. , 2011, European journal of endocrinology.

[17]  M. Ranke,et al.  Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. , 2010, The Journal of clinical endocrinology and metabolism.

[18]  P. Touraine,et al.  Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. , 2009, European journal of endocrinology.

[19]  J. Horowitz,et al.  The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. , 2009, The Journal of clinical endocrinology and metabolism.

[20]  Niels Møller,et al.  Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. , 2009, Endocrine reviews.

[21]  F. Darendeliler,et al.  Headache, Idiopathic Intracranial Hypertension and Slipped Capital Femoral Epiphysis during Growth Hormone Treatment: A Safety Update from the KIGS Database , 2007, Hormone Research in Paediatrics.

[22]  K. Boye,et al.  Impact of dose frequency on compliance and health outcomes: a literature review (1966–2006) , 2007, Expert review of pharmacoeconomics & outcomes research.

[23]  L. Hulthén,et al.  Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  Shumei S. Guo,et al.  2000 CDC Growth Charts for the United States: methods and development. , 2002, Vital and health statistics. Series 11, Data from the National Health Survey.

[25]  B. Silverman,et al.  A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. , 2001, The Journal of clinical endocrinology and metabolism.

[26]  M. Rotondi,et al.  Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections. , 2000, The Journal of clinical endocrinology and metabolism.

[27]  T. Cole.  Galton's midparent height revisited , 2000, Annals of human biology.

[28]  H. Guyda,et al.  Four decades of growth hormone therapy for short children: what have we achieved? , 1999, The Journal of clinical endocrinology and metabolism.

[29]  J. Jørgensen,et al.  Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH‐deficient patients , 1996, Clinical endocrinology.

[30]  J. Tanner,et al.  Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. , 1976, Archives of disease in childhood.

[31]  J M Tanner,et al.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. , 1966, Archives of disease in childhood.

[32]  J. Tanner,et al.  Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. , 1966, Archives of disease in childhood.

[33]  P. Lopez,et al.  24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency. , 2014, The Journal of clinical endocrinology and metabolism.

[34]  V. Montori,et al.  Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. , 2012, European journal of endocrinology.

[35]  W. Zipfel,et al.  In vivo delivery of fluoresceinated dextrans to the murine growth plate: imaging of three vascular routes by multiphoton microscopy. , 2006, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[36]  M. Harris,et al.  Growth Hormone Treatment in Children , 2004 .

[37]  Shumei S. Guo,et al.  CDC GROWTH CHARTS FOR THE UNITED STATES: METHODS AND DEVELOPMENT 2000 , 2002 .

[38]  K. Alberti,et al.  Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. , 1990, The Journal of clinical endocrinology and metabolism.